ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: Wynder Receives ACS Award At ASCO; Brinker to Be Honored for Public Service

May 23, 1997

Grants Funding: FY(& Year-End Report By NCI On Paylines

October 10, 1997

Clinical Trials Approved By NCI’s CTEP Listed

February 25, 2005

CT Scanning Use, Costs, Controls Debated By NCAB

October 7, 1977

In Brief: Hisserich Named USC Assistant VP, Replaced By Rideout At Cancer Center; DeVita Assures Groups

June 27, 1986

NCI To Fund 29% Of Grants In 1990, With Budget Cuts

February 17, 1989